1. Scrip
  2. >>Conferences
  3. >>J.P. Morgan

Vaccine Manufacturers Prepare To Fight Disinformation With Transparency

 
• By Jessica Merrill

At J.P. Morgan, GSK, Sanofi and Pfizer said they are prepared to address questions about vaccines under a new US administration, while former FDA commissioner Gottlieb warned of threats to public safety.

J.P. Morgan 2025
(Shutterstock)
Key Takeaways
  • Vaccine manufacturers are preparing for the possibility of increased misinformation about vaccines under the new Trump administration.  
  • Concerns about HHS Secretary nominee Robert F. Kennedy, Jr.’s opinions on vaccines were discussed at the J.P. Morgan Healthcare Conference.  
  • GSK CEO Emma Walmsley and Sanofi CEO Paul Hudson said transparency about the safety and efficacy of vaccines will be needed to counter any anti-vaccine sentiment.  

The future direction of the US Department of Health & Human Services (HHS) under Robert F. Kennedy, Jr. was a worry for many pharmaceutical executives at the J.P. Morgan Healthcare Conference

Former FDA commissioner Scott Gottlieb, who worked under the first Trump administration and was a featured speaker at the meeting, left no doubt that drug companies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from J.P. Morgan

BMS Enters A Catalyst-Rich Era Full Of Both LOEs And New Launches

 
• By Mandy Jackson

Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.

Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D

 
• By Mandy Jackson

Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.

Momentum In Women’s Health, But Big Obstacles Too

 
• By Jessica Merrill

Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.

Amgen Building On Repatha Experience As It Grows In Cardiovascular, Obesity

 
• By Mandy Jackson

Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.

More from Therapy Areas

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.